CSIMarket Company Name, Ticker, Industry, else..
 
Moleculin Biotech Inc   (NASDAQ: MBRX)
Other Ticker:  
 
 
Price: $0.8490 $0.02 2.413%
Day's High: $0.875 Week Perf: 10.26 %
Day's Low: $ 0.80 30 Day Perf: -24.87 %
Volume (M): 231 52 Wk High: $ 5.47
Volume (M$): $ 196 52 Wk Avg: $2.62
Open: $0.85 52 Wk Low: $0.40



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 3
 Employees 15
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) -19
 Capital Exp. (TTM) (Millions $) 0

Moleculin Biotech Inc
Moleculin Biotech Inc is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer therapies. The company is dedicated to addressing unmet medical needs through the development of potentially life-saving drugs. They primarily target highly resistant tumors with their proprietary small molecule technology platform.

Moleculin Biotech has a pipeline of multiple drug candidates, including Annamycin, WP1122, and WP1066, which have shown promising results in preclinical and early clinical studies. These candidates are designed to target specific proteins or tumor types, inhibiting tumor growth and promoting cancer cell death.

The company's flagship drug candidate, Annamycin, is being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML) and has shown potential to bypass multidrug resistance mechanisms observed in other chemotherapies. Moleculin Biotech is also exploring the potential applications of their technology platform in other types of cancer such as glioblastoma, pancreatic, and lung cancer.

In addition to their drug development efforts, Moleculin Biotech also collaborates with leading research institutions and cancer clinics to conduct clinical trials and further explore the potential of their drug candidates. The company aims to make a significant impact in the field of oncology by developing innovative therapies that can improve patient outcomes and quality of life.


   Company Address: 5300 Memorial Drive, Suite 950 Houston 77007 TX
   Company Phone Number: 300-5160   Stock Exchange / Ticker: NASDAQ MBRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.92%    
JNJ        3.78% 
LLY        14.68% 
MRK   -1.49%    
PFE        1.07% 
SNY   -1.19%    
• View Complete Report
   



Moleculin Biotech Inc

The Rise and Fall of Moleculin Biotech Inc: A Financial Analysis

Investors in Moleculin Biotech Inc (NASDAQ: MBRX) may have been taken by surprise with the changes in revenue during the January to March 31, 2024 reporting cycle. The shareholders did not anticipate these developments, and it raises concerns about the company's financial performance.
One significant factor that shareholders have been monitoring closely is the company's operating shortfall, which came in at a concerning $-6.677 million in the same period. While this may be seen as a positive surprise, as it is an improvement from the operating shortfall in the first quarter of 2023 ($-8.354 million), it is still a worrisome figure. This improvement does provide some assurance to market observers, highlighting Moleculin Biotech's efforts to address its financial challenges. However, it falls short of reaching better industry benchmarks.
Moleculin Biotech Inc

2. Uncertainty looms as Moleculin Biotech Inc. struggles with growing expenses in Q4 of 2023 Earnings Season

roduction
Moleculin Biotech Inc. (NASDAQ: MBRX), a renowned Houston-based clinical stage pharmaceutical company known for developing innovative drug candidates for hard-to-treat tumors and viruses, has recently reported disappointing earnings for the fourth quarter of the fiscal year 2023. With operating losses increasing, revenue concerns, and a significant decline in share prices, the company's growth trajectory appears uncertain.
Operating Losses and Depleted Revenue
During the fiscal period of October to December 31, 2023, Moleculin Biotech Inc. announced an operating loss of $-8.919 million for the fourth quarter. This represents an increase from the previous year's operating loss of $-7.048 million during the same period. Furthermore, the company faces speculation regarding its ability to generate revenue. Moleculin Biotech Inc. has diversified its business models in an attempt to secure steady revenue streams, suggesting that the current model may not be yielding the desired results.
Stock Offering

Moleculin Biotech, Inc. Accelerates Growth with Successful $4.5 Million Direct Offering and Private Placement

Published Thu, Dec 21 2023 2:16 AM UTC



Houston-based clinical stage pharmaceutical company, Moleculin Biotech, Inc., recently announced the successful pricing of a registered direct offering and concurrent private placement. The company specializes in a diverse range of drug candidates aimed at treating hard-to-treat tumors and viruses. This significant development showcases Moleculin s commitment to ad...
Moleculin Biotech Inc

Moleculin Biotech Inc. Surges Ahead with Promising Growth and Improved Operational Efficiency, Despite $5.9M Shortfall in Q3 2023



The recently released financial results of Moleculin Biotech Inc, a major player in the pharmaceutical preparations sector, indicate notable progress and potential for future growth. While the company reported an operating shortfall of $-5.947 million for the third quarter of 2023, the absence of top-line figures in their report leaves room for speculation. However, a closer analysis of their operational situation reveals improvements compared to the same period in 2022, indicating a positive trend.
Positive Operational Situation:
The primary observation from the financial results is the significant progress made by Moleculin Biotech Inc in the third quarter of 2023. Despite the lack of specific revenue figures, the company's ability to reduce the deficit to $-5.609 million showcases improved efficiency and better operational management. The company's executives have seemingly taken proactive measures to address financial challenges and bring the company closer to profitability.
Moleculin Biotech Inc

Moleculin Biotech Inc (MBRX) Surprises Market Observers with Improved Financial Performance in Q2 2023



In a sector dominated by major players, the Major Pharmaceutical Preparations sector, several smaller businesses have emerged with notable financial results. Moleculin Biotech Inc (MBRX) recently reported its financial earnings for the second quarter of 2023, revealing a positive surprise amidst a lack of usual comparisons. This article aims to delve into the financial facts and interpret the results to offer insight into the company's performance.
Financial Earnings:
MBRX disclosed an operating deficit of $-6.411 million for the second quarter of 2023. While a deficit is usually viewed negatively, when compared to the same reporting season a year ago, where the operating deficit stood at $-7.434 million, it becomes evident that MBRX has made significant progress in reducing its losses. This unexpected improvement in financial performance instills confidence among market observers regarding the company's management strategies.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com